Brief: Petosemtamab Granted Breakthrough Therapy Designation By The U.S. FDA

Merus NV

13/05/2024 13:11

May 13 (Reuters) - Merus NV  MRUS.O :
    * PETOSEMTAMAB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY
THE
U.S. FDA
    * MERUS NV: PETOSEMTAMAB GRANTED BTD FOR TREATMENT OF
PREVIOUSLY
TREATED HNSCC UTRECHT
    * MERUS NV: PLANS TO PROVIDE UPDATED EFFICACY, DURABILITY
AND
SAFETY DATA FROM THIS COHORT IN SECOND HALF OF 2024

Source text for Eikon:  ID:nGNX9WGdm1 
Further company coverage:  MRUS.O 

 ((Reuters.Briefs@thomsonreuters.com;))